Faria Capital Management
Biotech, small-cap, micro-cap, long/short equity

Ziopharm Joins The CAR Crowd

During their June 25th presentation at the JMP Securities Healthcare Conference (audio file), Dr. Lewis and Dr. Lebel spent a good chunk of their time discussing "the power of the platform" and Ziopharm's (NASDAQ:ZIOP) budding interest in chimeric antigen receptor CAR T cells. It wasn't clear at the time how the company would carry out their CAR ambitions, but many investors expected a partnership deal. More recently, Ziopharm put out a press release announcing their CAR program would move forward as a collaboration with Intrexon (NYSE:XON). Intrexon is already the source of Ziopharm's entire pipeline and owns 50% of any future revenue Ziopharm may earn. While Intrexon has spent a large percentage of their...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details